NanoViricides Highlights Broad-Spectrum Antiviral NV-387 After Hantavirus Scare

NanoViricides, Inc. (NYSE American: NNVC) has drawn attention to the urgent need for broad-spectrum antiviral treatments following a recent Andes hantavirus incident aboard a cruise ship. The company is positioning its clinical-stage antiviral candidate, NV-387, as a potential therapeutic platform to address emerging viral threats. NV-387 has successfully completed a Phase I safety and tolerability trial in healthy volunteers with no reported adverse events, and the company is now focused on advancing it into Phase II human clinical trials. The drug has demonstrated effectiveness in animal models against a wide range of viral lung infections, including coronaviruses, respiratory syncytial virus (RSV), influenza, monkeypox, and measles. This broad-spectrum activity underscores the potential of NV-387 as a versatile tool in combating future pandemics and bioterrorism threats.

NanoViricides is a clinical-stage company specializing in creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections. Additionally, NV-387 has shown efficacy in animal models for monkeypox, smallpox, and measles. The company also has another advanced candidate, NV-HHV-1, targeting herpesvirus infections such as HSV-1, HSV-2, shingles, and chickenpox. However, the company cannot project an exact date for filing an Investigational New Drug (IND) application due to dependence on external collaborators and consultants. The recent news release was distributed by BioMedWire (“BMW”), a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which provides a range of services including press release distribution, editorial syndication to 5,000+ outlets, and social media distribution.

The company’s emphasis on broad-spectrum antivirals comes at a critical time, as the world grapples with the constant threat of new and re-emerging viruses. The Andes hantavirus incident serves as a stark reminder that zoonotic diseases can appear unexpectedly, and effective treatments are needed that work across multiple viral families. With NV-387’s promising safety profile and broad efficacy in preclinical studies, NanoViricides is well-positioned to contribute to global pandemic preparedness. Investors can find the latest news and updates relating to NNVC in the company’s newsroom at https://ibn.fm/NNVC.